Black Diamond Therapeutics IncQ) expected to post a loss of 25 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
Black Diamond Therapeutics IncQ) is projected to report a loss of 25 cents per share for the quarter ending June 30, 2025, with no change in revenue. Analysts maintain a "buy" rating, with a median 12-month price target of $11.00, significantly above its last closing price of $2.66. The mean earnings estimate has dropped by 89.5% in the last three months. Previous quarterly performances have consistently beaten estimates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments